ATAD1

Across TCGA pan-cancer cohorts, ATAD1 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ATAD1 data layer compared with 26 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ATAD1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ATAD1 expression acts as an unfavorable survival marker, although some lineages such as UCEC and GBM show a favorable association.

PDAC, COAD, and UCEC are the cancer types where ATAD1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.582	0.878	.002	26	view →
COAD	DFS	Median	IV	0.493	0.944	.031	18	view →
UCEC	OS	Tertile	III,IV	1.000	0.291	.029	16	view →
GBM	DFS	Quartile	All	0.910	0.614	<.001	14	view →
LUAD	DFS	Quartile	II,III,IV	0.215	0.925	.002	6	view →
CCRCC	OS	Median	IV	0.150	0.785	.040	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ATAD1–PDAC (DFS)

Open the PDAC breakdown →